Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Karyopharm Therapeutics ( (KPTI) ).
Karyopharm Therapeutics Inc., a leader in innovative cancer therapies, is actively engaging with the FDA to discuss the implications of the evolving endometrial cancer treatment landscape on its Phase 3 XPORT-EC-042 trial. This trial is exploring selinexor as a maintenance therapy for advanced endometrial cancer. The company has announced it will update stakeholders post-discussion and has postponed any current conference presentations on the program.
See more insights into KPTI stock on TipRanks’ Stock Analysis page.
Trending Articles
- ‘Stay Away,’ Says Hans Mosesmann About Intel Stock
- Canaccord Pounds the Table on Archer Aviation Stock
- ‘Don’t Let the Law of Large Numbers Scare You,’ Says Top Investor About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
